ReviewVaccines2021
COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations.
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06646744 (Safety Study About the mRNA Vaccines Against COVID-19 in Pediatric Patients), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety Study About the mRNA Vaccines Against COVID-19 in Pediatric Patients (PEDIVACOV-HCSC)
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Clinical practice guidelines and expert consensus statements on rehabilitation for patients with COVID-19: a systematic review.BMJ open · 2024Pooled it
- Sequelae of COVID-19 among previously hospitalized patients up to 1 year after discharge: a systematic review and meta-analysis.Infection · 2022Pooled it
- Third dose of SARS-CoV-2 vaccine: A systematic review of 30 published studies.Journal of medical virology · 2022Pooled it
- Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: data from the Brazilian multicentric study safer.Advances in rheumatology (London, England) · 2024Trial
- Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.The Lancet. Infectious diseases · 2022Trial
- Contributions of prior health and vaccination to inequality in COVID-19 mortality by income: analysis of administrative microdata for the non-institutionalized Dutch population.International journal of epidemiology · 2026Article
- COVID-19 vaccine uptake in US adults with respiratory diseases: A cross-sectional study.Preventive medicine reports · 2026Article
- Vaccination protects against COVID-associated pulmonary fibrin deposition.Journal of virology · 2025Article
- A Study of Transplacental Transfer of SARS-CoV-2 Antibodies in COVID-19 Vaccinated Women in Mumbai, India.Cureus · 2025Article
- Article
- Efficacy and safety of casirivimab and imdevimab for preventing and treating COVID-19: a systematic review and meta-analysis.Journal of thoracic disease · 2024Article
- Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms.Heliyon · 2024Article
- The safety and immunogenicity of vaccines administered to pregnant women living with HIV: a systematic review and meta-analysis.EClinicalMedicine · 2024Article
- The disparity in hesitancy toward COVID-19 vaccination between older individuals in nursing homes and those in the community in Taizhou, China.BMC geriatrics · 2023Article
- Effect of Lymphocyte Phenotypic Alterations on the Humoral Response to Vaccination Against SARS-COV-2 in Dialysis Patients.Annals of laboratory medicine · 2023Article
- Anti-SARS-CoV-2 Antibody Level Is Associated with a History of COVID-19 Infection and mRNA Vaccination in Patients with Diabetes.Vaccines · 2023Article
- In-silico study: docking simulation and molecular dynamics of peptidomimetic fullerene-based derivatives against SARS-CoV-2 M3 Biotech · 2023Article
- The COVID-19 Vaccination Coverage in ICU Patients with Severe COVID-19 Infection in a Country with Low Vaccination Coverage-A National Retrospective Analysis.Journal of clinical medicine · 2023Article
- Review
- Cost-effectiveness analysis of vaccination against COVID-19 in China.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 has been spreading worldwide since late 2019. There is no definitive cure to date. Global vaccination programs are urgently required to confer herd immunity, reducing the incidence of COVID-19 infections and associated morbidity and mortality. However, a significant proportion of special populations are hesitant to receive vaccination due to their special conditions, namely, age (pediatrics and geriatrics), immunocompromised state, autoimmune diseases, chronic cardiovascular and pulmonary conditions, active or treated cancers, and pregnancy. This review aims to evaluate the existing evidence of COVID-19 vaccinations on these special populations and to provide clues to guide vaccination decision making to balance the benefits and risks of vaccinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.